行情

PHIO

PHIO

Phio Pharmaceuticals Corp
NASDAQ

实时行情|Nasdaq Last Sale

2.100
-0.220
-9.48%
已收盘, 16:00 03/27 EDT
开盘
2.390
昨收
2.320
最高
2.390
最低
2.020
成交量
6.99万
成交额
--
52周最高
28.88
52周最低
2.010
市值
517.95万
市盈率(TTM)
-0.0019
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PHIO价格均价为2.000,最高价位2.000,最低价为2.000。

EPS

PHIO 新闻

更多
  • 北欧富国66万人因疫情失业
  • 新浪财经 · 52分钟前
  • 摩根大通称风险资产市场大多已过了最黑暗时期
  • 新浪财经 · 1小时前
  • 未雨绸缪 韩国12月曾举行应对假想疫情演习
  • 新浪财经 · 1小时前
  • 特朗普:大量急需的抗疫物资运抵纽约,美媒:首批来自中国!
  • 环球网 · 1小时前

所属板块

生物技术和医学研究
-2.44%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

PHIO 简况

Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.
展开

微牛提供Phio Pharmaceuticals Corp(NASDAQ-PHIO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PHIO股票新闻,以帮助您做出投资决策。